Actively Recruiting
Alternative vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA)
Led by Phramongkutklao College of Medicine and Hospital · Updated on 2026-01-07
114
Participants Needed
1
Research Sites
133 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to compare the effectiveness and tolerability of two different oral iron regimens in adults with iron deficiency anemia (IDA). The main questions it aims to answer are: Is alternate-day oral iron supplementation as effective as once-daily dosing in improving hemoglobin levels? What are the side effects associated with each dosing regimen? Researchers will compare once-daily vs. alternate-day oral ferrous fumarate to evaluate whether alternate-day dosing is non-inferior in terms of hematologic response, with fewer adverse effects. Participants will: Be randomly assigned to take ferrous fumarate 200 mg once daily or 400 mg on alternate days for 8 weeks Undergo blood tests and clinical assessments at baseline, Week 4, and Week 8 Report any side effects and bring remaining pills to evaluate medication adherence This is a multicenter, randomized, open-label, non-inferiority trial conducted in adults aged 20 years or older with IDA.
CONDITIONS
Official Title
Alternative vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female patients aged 20 years diagnosed with iron deficiency anemia, defined as hemoglobin (Hb) <13 g/dL in males or <12 g/dL in females, and ferritin <50 ng/mL or transferrin saturation (TSAT) <20%
- No iron supplementation within the past 3 months
You will not qualify if you...
- Hemodynamic instability such as acute bleeding or low blood pressure
- Severe heart failure (New York Heart Association Class III-IV) or other active heart diseases
- Active cancer or history of cancer within the past 3 years except non-melanoma skin cancer
- Pregnancy or breastfeeding
- Chronic liver disease including cirrhosis (Child-Pugh class B or C)
- Chronic kidney disease with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m8
- Clinically significant thalassemia or other hemoglobin disorders
- Ongoing infection or chronic inflammatory diseases like rheumatoid arthritis or inflammatory bowel disease
- Malabsorption disorders such as history of bariatric surgery
- Red blood cell transfusion within the past 3 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Phramongkutklao Hospital
Bangkok, Thailand, 10400
Actively Recruiting
Research Team
T
Tanapun Thamgrang, Doctor of Medicine
CONTACT
A
Aticha Kraiput, Doctor of Medicine
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here